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Abstract
Background: Antibiotic homogeneity is thought to drive resistance but in vivo data are lacking. In this study, we determined
the impact of antibiotic homogeneity per se, and of cefepime versus antipseudomonal penicillin/b-lactamase inhibitor
combinations (APP-b), on the likelihood of infection or colonisation with antibiotic resistant bacteria and/or two commonly
resistant nosocomial pathogens (methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa). A secondary
question was whether antibiotic cycling was associated with adverse outcomes including mortality, length of stay, and
antibiotic resistance.
Methods: We evaluated clinical and microbiological outcomes in two similar metropolitan ICUs, which both alternated
cefepime with APP-b in four-month cycles. All microbiological isolates and commensal samples were analysed for the
presence of antibiotic-resistant bacteria including MRSA and P. aeruginosa.
Results: Length of stay, mortality and overall antibiotic resistance were unchanged after sixteen months. However,
increased colonisation and infection by antibiotic-resistant bacteria were observed in cefepime cycles, returning to baseline
in APP-b cycles. Cefepime was the strongest risk factor for acquisition of antibiotic-resistant infection.
Conclusions: Ecological effects of different b-lactam antibiotics may be more important than specific activity against the
causative agents or the effect of antibiotic homogeneity in selection for antibiotic resistance. This has important
implications for antibiotic policy.
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Introduction
Immediate effective antibiotic therapy is one of the most
important intervention in severe sepsis, but ultimate survival is
determined before cultures become positive and antibiotic
susceptibilities available [1,2]. Broad-spectrum antibiotics such
as carbapenems (e.g. meropenem), antipseudomonal penicillin/b-
lactamase inhibitor combinations (APP-b) like piperacillin/
tazobactam (TZP) and ticarcillin/clavulanate (TIM), and
broad-spectrum cephalosporins such as cefepime are commonly
used, but are restricted in many countries, with the aim of
minimising development of antibiotic resistance.
The clinical benefit of antibiotic-intensive strategies such as
selective decontamination of the digestive tract [3] comes at the
cost of increased antibiotic resistance in the microflora [4].
Conversely, antibiotic restriction may reduce antibiotic resistance.
In the ‘‘antibiotic cycling’’ strategy, potent antibiotics are
alternated in order to allow specific resistance to subside. Initially
promising reports [5] have been followed by numerous studies
with mixed results. A study comparing 4-month cycles of
carbapenems, third-generation cephalosporins and APP-b sug-
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selection pressure and resistant infection [6], while another using
carbapenems, quinolones, cephalosporins and APP-b found no
increase in resistance in the microflora during or after the cycling
period [7]. Expert reviewers conclude that more data are needed,
as many questions remain unanswered [8,9], but mathematical
models of antibiotic cycling predict that homogeneous selection
pressure will increase antibiotic resistance [10,11].
Our primary aim was to determine whether cycles of relatively
homogeneous b-lactam use, alternating cefepime and APP-b as
the core of empiric antibiotic therapy for sepsis in ICU, resulted in
increased antibiotic resistance. We defined this as the acquisition
at any site of either MRSA or P. aeruginosa (two commonly resistant
nosocomial pathogens) or of any bacteria resistant to cefepime,
APP-b, or gentamicin, and considered these separately. A
secondary aim was to determine whether the institution of
antibiotic cycling in ICU was associated with adverse clinical
outcomes, specifically relating to mortality and length of stay, in
light of previous findings of increase mortality associated with
empiric use of cefepime in the critically ill [12].
Methods
Study Design and Population
We varied the b-lactam component (cefepime vs APP-b)o f
empiric antibiotic prescribing in four month cycles in two well-
matched high-acuity metropolitan Australian ICUs. No attempt
was made to influence prescribing for known or suspected
aetiologies, but those judged in need of empiric broad-spectrum
b-lactam therapy by the caring physician received cycle-specified
b-lactam (cefepime or APP-b) with other antibiotics as deemed
appropriate. Standard infection control procedures applied,
according to matching guidelines in both institutions. Approval
to conduct the study, under a waiver of consent, was obtained
from the relevant Human Research Ethics Committees of the
Sydney West Area Health Service and the Royal Brisbane and
Women’s Hospital.
There were four consecutive cycles in Unit 1 (Westmead, WM),
beginning in April 2004 (cefepime), August (APP-b), December
(cefepime), and April 2005 (APP-b), respectively (Figure 1), and
three in Unit 2 (Royal Brisbane and Women’s Hospital, RBWH),
beginning in August 2004 (APP-b), December 2004 (cefepime) and
April 2005 (APP-b). For a short period (February to March 2005),
nationwide shortages of piperacillin/tazobactam (TZP) meant
substitution with ticarcillin/clavulanate (TIM) as the APP-b,a s
these agents are generally regarded as closely comparable in their
antibacterial spectra [13]. Hereafter the term APP-b is used for
both.
Of the 1987 admissions to both ICUs in this period, 1194 were
for at least 48 hours. Of these, 286 were admitted within 48 h of
hospital arrival and received only cefepime or APP-b,o rn o
antibiotics at all, by the end of their first week in ICU. In 206 of
these (72%), late clinical followup and microbiological surveillance
(see below) at all timepoints was complete. This group represents
patients most clearly and directly subject to cycle-specific antibiotic
influences. Data collected included age, sex, admission Acute
Physiology and Chronic Health Evaluation (APACHE II) score,
reason for admission, surgical and other interventions, ventilation
and dialysis days, presence of central venous catheters, dialysis
catheters, hospital and ICU length of stay (LOS), mortality,
detailed antibiotic treatment, and microbiological information
(Table 1). The standardised APACHE score remains the premier
predictor of ICU and hospital mortality for ICU admissions with
high predictive value [14] and high inter-rater reliability [15].
APACHE II [16] incorporates a range of acute (temperature,
mean arterial pressure, blood pH, heart and respiratory rate,
arterial-alveolar oxygen gradient, serum Na, K, Creatinine, white
blood count, haematocrit, Glasgow Coma Score, presence of acute
renal failure) and chronic indicators (age, hepatic failure,
encephalopathy, cirrhosis, portal hypertension, heart failure,
dialysis, chronic respiratory failure and respiratory conditions,
and immunosuppression including leukaemia, lymphoma or
AIDS). Antibiotic use, recorded as numbers of patients treated
and as defined daily doses (DDD), included days on which the
antibiotic regimen started and ended. Antibiotic doses were
adjusted up and down from the standard guidelines by the duty
intensive care specialist on the basis of usual pharmacokinetic
considerations (renal and hepatic function, dialysis, volumes of
distribution, protein binding) in individual patients, but antibiotic
levels in blood and tissues were routinely measured only for
aminoglycosides and vancomycin. All antibiotics, including
vancomycin and gentamicin, were otherwise dosed and monitored
according to standard Australian guidelines [13]. Cefepime dosing
was recommended at 6 g/day (2 g every 8 h) for severe infection,
and piperacillin 4 g plus tazobactam 500 mg (TZP 4.5 g) every
8 h or ticarcillin 3 g/clavulanate 100 mg (TIM 3.1 g) every 6 h
for an average person with normal renal function.
Microbiological Analysis
Positive cultures from all clinically indicated specimens submit-
ted to the diagnostic laboratory were identified. Respiratory tract
isolates were reported as significant if a pathogen was identified as
sufficiently numerous in semi-quantitative assays ($10
4 cfu/mL in
non-bronchoscopic or directed bronchoalveloar lavage) or was
predominant in a purulent sputum specimen without significant
epithelial contamination evident (,10 epithelial cells per high-
power field) on microscopy. Isolates were also deemed significant if
Figure 1. b-lactam use in cycle periods. Relative distribution of
antibiotic use (defined daily doses) among the major b-lactams:
cefepime (FEP), antipseudomonal penicillin combinations (APP-b),
meropenem (MEM), and ceftriaxone or cefotaxime (CTX) use in the
combined Units (n=1987).
doi:10.1371/journal.pone.0038719.g001
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predominant in the specimen on microscopy and culture (e.g.,
deep tissues) or if pyuria was present and .10
6 cfu/mL of a single
organism was grown from urine. The reporting laboratory must
also have issued full identification and susceptibility data on the
basis of established standard laboratory criteria in both centres, in
accordance with established definitions [17] by prior agreement
between investigators in both units.
All specimens were given unique numbers and de-identified
before processing. Surveillance samples (perineal swab and
endotracheal aspirate) obtained on admission and twice weekly
thereafter were submitted to the centralised reference laboratories
serving each unit (Unit 1: Centre for Infectious Diseases and
Microbiology (CIDM) Laboratory Services at Westmead Hospital,
Sydney; Unit 2: Queensland Pathology at the Royal Brisbane and
Women’s Hospital, Brisbane), and inoculated into nutrient broth
overnight, resuspended in 20% glycerol in nutrient broth (GNB,
Difco) and stored at -80uC for transfer to CIDM. A loopful of each
frozen sample was resuspended in nutrient broth at 37uC for
90 min aerobically before inoculation onto solid media. Pseudomo-
nas aeruginosa was confirmed by growth on Pseudomonas Isolation
Agar (Becton Dickinson) [18] and oxidase activity (Oxoid), and
methicillin-resistant Staphylococcus aureus (MRSA) by growth on
Brilliance MRSA Agar (Oxoid) [19] with confirmatory testing
using the BactiStaph reagent (Remel) [20]. MRSA isolates were
subtyped by SmaI PFGE as previously described [21] and analysed
for relatedness as per standard criteria [22]. Enterobacteriaceae were
detected by their morphology on chromogenic agar (CHROMa-
gar Orientation) [23], and tested for growth in the presence of
ticarcillin/clavulanate (128/2 mg/mL), gentamicin (10 mg/mL) or
cefepime (64 mg/mL) incorporated into the agar. Colonies with
the typical appearance of E. coli or of Klebsiella/Enterobacter/Serratia/
Citrobacter spp. on CHROMAgar, in accordance with the
Australian National Accreditation Testing Authority approved
methodology in each laboratory and with the media manufactur-
er’s guidelines, were designated ‘‘Enterobacteriaceae’’ after testing to
exclude oxidase activity. All clinical isolates of P. aeruginosa and all
TIM-resistant P. aeruginosa isolates from surveillance samples, as
well a random subset of TIM-resistant Enterobacteriaceae, were also
tested against TZP. No significant differences were found in
antimicrobial susceptibility so TIM was retained as the APP-b
resistance marker. Unless otherwise specified in the text, ‘resistant’
or ‘resistance’ refers to APP-b, gentamicin and/or cefepime, in the
above concentrations. All MRSA isolates were resistant to these
three antibiotics, but P. aeruginosa isolates were specified as
‘resistant’ if resistant to any.
Statistical Analysis
Acquisition of infection and/or colonisation by antibiotic-
resistant bacteria and by P. aeruginosa and methicillin-resistant
S. aureus was the primary outcome for analysis. Each significant
isolate and each antibiotic-resistant colonisation was counted only
once per admission. Data were analysed separately for both
hospitals before being pooled, as the differences between the two
Table 1. Patient characteristics.
Characteristic Unit 1 (n=1135) Unit 2 (n=852) p
c All admissions (n=1987)
Age (years) median (IQR) 59.5 (41.1–71.6) 57.8 (40.1–70.9) 0.203 58.7 (40.8–71.3)
Male, n (%) 690 (60.8) 522 (61.3) 0.433 1212 (61.0)
ICU LOS (days) median (IQR) 3.2 (1.5–7.3) 2.2 (1.0–6.4) ,0.001 2.8 (1.2–6.9)
HOS LOS (days) median (IQR) 17.5 (6.6–39.0) 16.3 (7.1–32.7) 0.529 17.0 (7.0–36.1)
APACHE II median (IQR) 20.0 (14.0–26.0) 18.0 (13.0–24.8) 0.005 19.0 (13.0–25.0)
Admission from community ,48 h, n (%) 664 (58.5) 613 (71.9) ,0.001 1277 (64.3)
Admission category: Trauma/surgical, n (%) 650 (57.3) 472 (55.4) 0.411 1122 (56.5)
Medical, n (%) 485
a (42.7) 380 (44.6) 0.411 865 (43.5)
ICU Readmission, n (%) 47 (4.1) 45 (5.3) 0.138 92 (4.6)
Multiple ICU Readmissions, n (%) 19 (1.7) 10 (1.2) 0.234 29 (1.5)
Operative Intervention, n (%) 314 (27.7) 540
b (63.4) ,0.001 854 (43.0)
Intercranial drain or monitor, n (%) 56 (4.9) 74 (8.7) 0.001 130 (6.5)
Intercostal Drain, n (%) 40 (3.5) 80 (9.4) ,0.001 120 (6.0)
Nasogastric catheter, n (%) 864 (76.1) 657 (77.1) 0.323 1521 (76.5)
Endotracheal Tube or Tracheostomy, n (%) 842 (74.2) 629 (73.8) 0.448 1471 (74.0)
Urinary catheter, n (%) 913 (80.4) 819 (96.1) ,0.001 1732 (87.2)
Arterial catheter, n (%) 889 (78.3) 797 (93.5) ,0.001 1686 (84.9)
Central venous catheter, n (%) 836 (73.7) 594 (69.7) 0.3 1430 (72.0)
Other vascular (dialytic) catheter, n (%) 95 (8.4) 86 (10.1) 0.207 181 (9.1)
Dialysis, n (%) 92 (8.1) 84 (9.9) 0.176 176 (8.9)
ICU Mortality, n (%) 137 (12.1) 112 (13.1) 0.258 249 (12.5)
Hospital Mortality, n (%) 165 (14.5) 136 (16.0) 0.208 301 (15.1)
Patient characteristics of all admissions.
aincludes haematology/marrow transplant (,1% of admissions to both units);
bincludes tracheostomies;
cMann-Whitney U test or Chi-Squared analysis.
doi:10.1371/journal.pone.0038719.t001
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Table 1). Statistical analysis was performed using SPSS (v18, SPSS
Inc.). Proportions were compared using the Mann-Whitney U,
one-way analysis of variance (ANOVA) or Chi-Squared tests, as
specified. Analysis of multiple predictors for ICU clinical and
bacteriological outcomes was performed using step-wise back-
wards logistic regression models, considering only those factors
significant at p#0.10 in univariate analysis, and retaining only
factors significant at p#0.05 in the final model.
Results
The Study Population
Admissions to Unit 1 (n=1135) and Unit 2 (n=852) were
similar in casemix and other key characteristics (Table 1), and
were combined for most analyses. Illness severity was moderately
high, with median APACHE II scores of 20 (IQR 14–26) vs. 18
(IQR 13–25), ICU mortality rates of 12.1% vs. 13.1% and in-
hospital mortality of 14.5% vs. 16.0% for Units 1 and 2,
respectively. Predictors of mortality within the set of all admissions
(n=1987) by multivariate analysis were age.65 (OR 1.45; 95%
CI 1.10–1.90), endotracheal intubation for mechanical ventilation
(OR 1.59; 95% CI 1.14–2.23) and renal failure requiring dialysis
(OR 2.92; 95% CI 1.89–4.53), all p,0.01. Surgical admissions
were associated with a relatively lower mortality risk (OR 0.49;
95% CI 0.37–0.65; p,0.001).
Antibiotic Homogeneity and Main Outcomes
Antibiotic homogeneity was high: cycle-specified drug com-
prised .60% of major b-lactam antibiotic use in respective on-
cycles and ,15% in off-cycles (Figure 1). Other antibiotic use was
generally consistent between cycles (Figure 2). Unit 2 had
significantly more admissions from the community (71.9 vs
58.5%) and a higher incidence of urinary catheterisation (96.1 vs
80.4%), but there were no other important differences in major
demographic or casemix variables, and no significant differences
in infection rates, mortality or length of stay, either between cycles
or from beginning to end-study, when data from both Units were
considered together (Table 2 and 3). The final cycle had the most
patients, the highest proportion mechanically ventilated (Table 2),
the highest antibiotic use, and the highest treatment intensity
(cycle 1:2449 DDD/1965 patient days, ratio 1.25; cycle 2:4656/
3737, 1.25; cycle 3:5012/3656, 1.37; cycle 4 4830/3362, 1.44;
Table 4). Despite this, the proportion of admissions complicated
by infection in the last (APP-b) cycle was unchanged in Unit 1, and
reduced in Unit 2 when compared to previous cycles (Table 3).
Risk of Infection by Resistant Bacteria is Higher in
Cefepime Cycles
In order to determine the impact of the two different b-lactam
regimens, we compared the risk of infection and/or colonisation
with either MRSA or P. aeruginosa or other antibiotic resistant
bacteria. Two hundred and twenty-three admissions in all were
complicated at some stage by resistant infection. Of all infecting
bacteria resistant to any of the three first-line antibiotics, APP-b
(isolated from n=121, 54.3% of admissions) and gentamicin
resistance (132, 59.2%) were most common. Cefepime resistance
was rare among Enterobacteriaceae (2, 0.9%) and P. aeruginosa (11,
4.9%). A cefepime-resistant infection complicated only 32 (14.3%)
admissions. Forty-one (18.4%) of the 223 admissions complicated
by resistant infection were complicated by antibiotic-resistant
P. aeruginosa and 81/223 (36.3%) by MRSA.
Although there was no difference in the proportion of
admissions complicated by any infection at all, the proportion of
admissions complicated by antibiotic-resistant infection was more
than twice as high in cefepime cycles as in APP-b cycles (164.1 vs
74.2 per 1000 admissions; p,0.001). MRSA infection complicated
significantly more cefepime than APP-b cycle admissions (116.3 vs.
72.2/1000 admissions; p 0.01), and this was also evident between
individual cycles (Table 3). P. aeruginosa infection (any/all,
including gentamicin and APP-b susceptible) complicated a
greater proportion of admissions in cefepime than APP-b cycles
(Table 3), and this was statistically significant in Unit 1, although
analysis according to resistance phenotype was not statistically
meaningful. A similar trend in both Units for increased infection
by (any/all) P. aeruginosa in cefepime cycles (cefepime vs APP-b:
98.8 vs 69.3/1000; Table 3) was not statistically significant (p
0.07).
Fourteen cefepime-cycle admissions were complicated by
antibiotic-resistant bacteraemia compared to nine APP-b-cycle
admissions although the difference between these small numbers
was not significant (16.6 vs 7.9 per 1000 admissions; p 0.089).
About a third of all bacteraemias (10/35, Unit 1; 5/12, Unit 2)
were due to Enterobacteriaceae but few were antibiotic-resistant and
these were not further analysed.
Risk of Colonisation by Resistant Bacteria is higher in
Cefepime Cycles
Increased infection in those exposed to cefepime should be
associated with increased colonisation rates. We identified
admissions direct from the community who received either
specified b-lactam (and no off-cycle b-lactam) for .48 hours
before sampling in the first week of admission, or no antibiotics at
all (60/152, 39% of APP-b cycle admissions; 58/134, 43% of
cefepime cycle admissions). This subset (n=286), with higher
admission APACHE II scores and ICU length of stay (Table S1),
most accurately reflects antibiotic influence. When data were
pooled and compared by cycle type, there were no significant
differences in overall proportions of admissions in which MRSA or
P. aeruginosa was isolated from surveillance samples (Table 3).
However, when the first, middle and final thirds of each cycle are
plotted to account for ‘washout’ from the preceding cycle, a trend
Figure 2. Antibiotic usage. Total defined daily doses in each cycle
(n=1987) in Unit 1 (above line) and Unit 2 (below line); black bars, FEP
cycles; white bars, APP-b cycles; AMP, ampicillin; APP-b, antipseudo-
monal penicillin combinations; FEP, cefepime; CRO, ceftriaxone; CTX,
cefotaxime; FLU, flucloxacillin; DCX, dicloxacillin; MEM, meropenem;
AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin;
MXF, moxifloxacin; VAN, vancomycin; MTZ, metronidazole.
doi:10.1371/journal.pone.0038719.g002
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Characteristic Cycle 1 (n=284) Cycle 2 (n=571) Cycle 3 (n=557) Cycle 4 (n=575)
Age (yrs); Median (IQR) 60.5 (14.0–72.0) 60.5 (39.9–71.9) 55.5 (39.6–71.7) 58.5 (40.9–70.0)
d*
Male, n (%) 160 (56.3)
a* 368 (64.4) 336 (60.3) 348 (60.5)
ICU LOS (days); Median (IQR) 3.0 (751.0–7.3) 2.6 (1.0–6.8) 2.9 (1.8–7.5) 2.8 (1.4–6.8)
Hospital LOS (days); Median (IQR) 17.0 (7.0–37.9) 16.5 (6.9–35.7) 16.8 (7.3–34.8) 17.7 (6.0–37.2)
Age .65 years, n (%) 112 (39.4) 229 (40.1) 193 (34.6) 195 (33.9)
APACHE II; Median (IQR) 20.0 (1.5–26.0) 18.0 (13.0–26.0) 19.0 (13.0–25.5) 18.0 (13.0–24.0)
Admission from community ,48 h, n (%) 145 (51.1)
a*** 372 (65.1) 377 (67.7) 384 (66.8)
d***
Admission category: Trauma/surgical, n (%) 159 (56.0) 328 (57.4) 322 (57.8) 313 (54.4)
Medical, n (%) 125 (44.0) 243 (42.6) 235 (42.2) 262 (45.6)
ICU Readmission, n (%) 14 (4.9) 30 (5.3) 23 (4.1) 25 (4.3)
Multiple ICU Readmissions, n (%) 6 (2.1) 15 (2.6)
b** 3 (0.5) 5 (0.9)
Operative Intervention, n (%) 76 (26.8)
a*** 257 (45.0) 246 (44.2) 275 (47.8)
d***
Intercranial drain or monitor, n (%) 19 (6.7) 36 (6.3) 31 (5.6) 44 (7.7)
Intercostal Drain, n (%) 15 (5.3) 37 (6.5) 38 (6.8) 30 (5.2)
Nasogastric catheter, n (%) 196 (69.0) 4.9 (71.6) 426 (76.5)
c*** 490 (85.2)
d***
Endotracheal Tube or Tracheostomy, n (%) 205 (72.2) 391 (68.5) 401 (72.0)
c*** 474 (82.4)
d***
Urinary catheter, n (%) 221 (77.8)
a* 480 (84.1) 486 (87.3)
c*** 545 (94.8)
d***
Arterial catheter, n (%) 215 (75.7)
a** 479 (83.9) 471 (84.6)
c* 521 (90.6)
d***
Central venous catheter, n (%) 217 (76.4)
a** 383 (67.1) 394 (70.7) 436 (75.8)
Other vascular (dialytic) catheter, n (%) 14 (4.9) 40 (7.0) 44 (7.9) 44 (7.7)
Dialysis, n (%) 13 (4.6) 25 (4.4) 38 (6.8) 32 (5.6)
ICU Mortality, n (%) 47 (16.5) 66 (11.6) 56 (10.1) 80 (13.9)
Hospital Mortality, n (%) 63 (22.2)
a*** 72 (12.6) 67 (12.0)
c* 99 (17.2)
aSignificant difference between cycle 1 (Unit 1 only) and 2;
bbetween cycle 2 and 3;
cbetween cycle 3 and 4;
dbetween cycle 1 and 4;
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0038719.t002
Table 3. MRSA and P. aeruginosa infection and colonisation after ICU admission.
all SI P. aerug. (SI) MRSA (SI) P. aerug. (CI) MRSA (CI)
Unit Cycle Adm. (rate) n (rate; % SI) n (rate; % SI) n/tested (rate) n/tested (rate)
1 1 FEP 180 34.44 14 7.78 24 13.33 18/51 26/51
(n=743) 2 APP-b 181 36.46 7 3.87 15 8.29 21/49 23/49
3 FEP 182 35.71 13 7.14 28 15.38* 23/57 23/57
4 APP-b 200 33.00 7 3.50 18 9.00* 22/52 20/52
All FEP 362 35.08 27 (7.46; 21.3) 52 (14.36; 40.1) 41/108 (38.9) 49/108 (48.1)
All APP-b 381 34.65 14 (3.67*; 10.6) 33 (8.66*; 25.0) 43/101 (42.6) 43/101 (42.6)
2 2 APP-b 144 80.15 20 13.89 8 5.56 6/31 0/31
(n=451) 3 FEP 154 77.12 24 15.58 8 5.19 3/26 0/26
4 APP-b 153 55.56* 13 8.50 8 5.23 5/20 1/20
All FEP 154 77.12 24 (15.58; 20.3) 8 (5.19; 6.8) 3/26 (11.5) 0/26 (0.0)
All APP-b 297 67.50* 33 (11.11; 17.5) 16 (5.39; 8.5) 11/51 (21.6) 1/51 (2.0)
Significant isolates (SI) in patients admitted for more than 48 h (n=1194;) compared with commensal isolates (CI) from those admitted to ICU within 48 h of hospital
arrival and received only cefepime or APP-b, or no antibiotics at all, by the end of their first week in ICU (n=286). FEP, cefepime; APP-b, antipseudomonal penicillin/b-
lactamase inhibitor combinations;
*indicatessignificance(p-value,0.05)relativetothepreviouscycle,byChi-Squaredanalysis.Rate:patientspositiveper100admissions;%SI:rateper100significantisolates.
doi:10.1371/journal.pone.0038719.t003
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Cycle 1 n (days) Cycle 2 n (days) Cycle 3 n (days) Cycle 4 n (days)
Antibiotic First Mid Last First Mid Last First Mid Last First Mid Last
PEN 1 (2) 0 (0) 0 (0) 7 (22) 8 (56) 5 (26) 1 (1) 8 (28) 5 (11) 4 (19) 11 (46) 13 (59)
AMP 9 (35) 6 (14) 9 (22) 12 (48) 12 (19) 13 (39) 25 (88) 23 (112) 23 (60) 19 (76) 10 (46) 5 (15)
CEF/CFZ 20 (49) 24 (69) 17 (31) 44 (136) 30 (79) 46 (121) 37 (99) 43 (136) 41 (115) 30 (83) 34 (127) 35 (123)
FLU/DCX 1 (6) 5 (21) 6 (32) 10 (36) 9 (34) 8 (46) 5 (12) 9 (53) 6 (25) 8 (31) 4 (21) 7 (23)
CAZ 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 1 (3) 1 (3) 0 (0) 0 (0) 3 (20) 2 (3) 1 (2)
CTX/CRO 15 (54) 17 (48) 14 (47) 27 (105) 15 (59) 15 (42) 23 (91) 10 (24) 15 (51) 21 (90) 18 (52) 20 (52)
FEP 21 (133)3 8 ( 273)2 6 ( 202) 5 (31) 3 (31) 3 (26) 68 (409)6 8 ( 425)5 7 ( 342) 7 (50) 3 (13) 3 (12)
APP-b 4 (29) 6 (49) 6 (23) 72 (423)6 3 ( 357)7 0 ( 346) 23 (112) 18 (66) 15 (75) 70 (440)6 6 ( 300)8 2 ( 539)
MEM 7 (29) 3 (11) 4 (23) 21 (167) 14 (56) 17 (127) 11 (65) 17 (139) 13 (92) 26 (261) 13 (91) 16 (115)
AMK 1 (5) 1 (4) 3 (3) 1 (2) 0 (0) 1 (2) 1 (10) 0 (0) 2 (2) 0 (0) 2 (8) 1 (3)
GEN 21 (105) 26 (112) 23 (70) 46 (190) 50 (211) 38 (167) 40 (139) 38 (169) 55 (269) 38 (149) 39 (119) 47 (197)
TOB 0 (0) 0 (0) 0 (0) 0 (0) 6 (46) 2 (4) 1 (2) 1 (3) 2 (4) 4 (27) 2 (2) 1 (1)
MTZ 23 (146) 32 (165) 28 (102) 24 (142) 27 (135) 21 (91) 52 (220) 52 (281) 49 (215) 31 (117) 34 (127) 22 (96)
CIP 3 (15) 5 (28) 1 (2) 13 (114) 6 (41) 8 (62) 8 (32) 3 (10) 8 (64) 13 (115) 10 (44) 10 (62)
MXF 8 (36) 7 (57) 8 (36) 15 (82) 2 (12) 4 (14) 6 (27) 9 (43) 6 (22) 7 (38) 6 (43) 7 (32)
TEC 0 (0) 0 (0) 1 (3) 1 (7) 1 (5) 2 (10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VAN 26 (122) 29 (134) 21 (96) 53 (323) 40 (224) 41 (249) 45 (243) 43 (225) 48 (278) 46 (322) 49 (173) 56 (285)
LZD 0 (0) 0 (0) 0 (0) 0 (0) 1 (34) 0 (0) 2 (10) 0 (0) 3 (64) 1 (42) 3 (7) 1 (8)
SXT 0 (0) 1 (6) 0 (0) 0 (0) 1 (2) 1 (5) 1 (1) 3 (27) 2 (18) 5 (31) 4 (27) 4 (46)
CST 0 (0) 0 (0) 0 (0) 0 (0) 1 (46) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total antibiotic days/
patient days (ratio)
2449/1965 (1?25) 4656/3737 (1?25) 5012/3656 (1?37) 4830/3362
(1?44)
Number of patients receiving specified antibiotic in each cycle, n, and total patient days (days).
First: first third of cycle; mid: middle third of cycle; last: last third of cycle.
PEN, penicillin; AMP, ampicillin; CEF, cephalothin; CFZ, cefazolin; FLU, flucloxacillin; DCX, dicloxacillin; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FEP, cefepime;
APP-b, antipseudomonal penicillin combinations; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; MTZ, metronidazole; CIP, ciprofloxacin; MXF,
moxifloxacin; TEC, teicoplanin; VAN, vancomycin; LZD, linezolid; SXT, co-trimoxazole; CST, colistin (polymixin E).
doi:10.1371/journal.pone.0038719.t004
Figure 3. Antibiotic treatment and P. aeruginosa and MRSA colonisation rates. Total defined daily doses of selected antibiotics in cycle
thirds in patients admitted to ICU within 48 h of hospital arrival and received only cefepime or APP-b, or no antibiotics at all, by the end of their first
week in ICU (vertical bars; left axis), with incidence rates (solid lines; right axis) of unique isolation of MRSA (triangles) and P. aeruginosa (squares) from
commensal sites (ie. colonisation rates, per 100 admissions).
doi:10.1371/journal.pone.0038719.g003
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significantly different when directly compared (Table 5).
Sampling was complete at all time points in 206 of these 286
admissions. Of these 206, 63 (30.6%) developed perineal and/or
endotracheal colonisation by antibiotic-resistant bacteria in the
first week. Of 63 newly colonised admissions identified, 18 (28.6%)
acquired MRSA, 36 (57.1%) acquired P. aeruginosa and 44 (69.8%)
acquired resistant Enterobacteriaceae. Backwards stepwise logistic
regression analysis revealed cefepime treatment in a cefepime cycle
as the sole independent predictor of acquiring resistant bacteria at
surveillance sites (OR 2.51; 95% CI 1.35–4.66; p 0.003). Those
treated with cefepime were significantly more likely to acquire
MRSA (OR 3.612; 95% CI 1.33–9.79; p 0.012) or antibiotic-
resistant Enterobacteriaceae (OR 3.184; 95% CI 1.589–6.380;
p 0.001). New acquisition of (any) P. aeruginosa was also twice as
common in the cefepime than APP-b -treated admissions, but this
was not quite statistically significant at 95% confidence levels (OR
2.02; 95% CI 0.96–4.23; p 0.063). The only factor associated with
reduced risk of antibiotic-resistant colonization was an operative
intervention (OR 0.049; 95% CI 0.241–0.990; p 0.047). Although
APP-b treatment did not independently predict reduced risk,
cefepime treatment is independently predictive of increased risk of
resistance acquisition in multivariate analysis.
Diversity of MRSA Subtypes
Clonal MRSA outbreaks that were coincidental with the
antibiotic cycle changes were excluded as an explanation for
these findings. Standardised methodology [22] revealed 35
distinct MRSA pulsotypes, within 17 clearly unrelated groups
(,84% similarity; Dice coefficient, represented by UPGMA,
0.5% optimization and 1.0% tolerance) that were distributed
throughout the study. The majority of these (,75%) were
members of the dominant clonal complex in Australia (Aus 2/3;
multi-locus sequence type 239), with complexes 93, 30, 22, 5 and
36 also identified. Diversity was similar in each cycle: cycle 1
(cefepime; Unit 1 only) had 7 PFGE variants of #95% similarity,
cycle 2 (APP-b) had 10 such variants, cycle 3 (cefepime) had 13
variants and cycle 4 (APP-b) had 11 variants. The largest group
of closely related isolates ($95% similarity) spanned two cycles
over a 6-month period (Mar - Sept 2004). This group comprised
only 20% of isolates in that period, were interspersed with less
closely related isolates, and still occurred sporadically a year later
(Figure S1). These data indicate that different MRSA clones
appeared throughout the study, as expected for a general
selection effect.
Discussion
The model of antibiotic cycling is part of normal ICU practice,
and in similar studies [24,25] a waiver of consent was granted for
the same reasons as apply here. Here, we show that cefepime
exposure is the strongest single independent risk factor for
colonization and infection of intensive care patients by antibiot-
ic-resistant bacteria. We found no evidence of a cumulative or
persistent effect, in keeping with a similar TZP/cefepime cycling
study in transplant patients that reported preservation of antibiotic
susceptibility among Gram-negative bacteria [26].
We found no support for mathematical models that identify
antibiotic homogeneity as a specific resistance driver [27]. This
conflict may be explained by the necessity to employ simplified
assumptions about biological mechanisms [28]. Previous studies
of antibiotic cycling often compared antibiotics with vastly
different mechanisms of action and ecological effects, and often
used extremely short cycles [29] in spite of evidence that
antibiotic effects last for many weeks and, for some elements of
the microflora, months to years [30]. Activity of cefepime against
relevant pathogens was superior to that of APP-b in vitro but
APP-b seem to have less adverse effects on the microflora than
third-generation cephalosporins [27,30]. Antibiotic levels in
tissues or gut were not defined in this study, but biliary
penetration of cefepime is relatively poor compared to that of
the antipseudomonal penicillins [31]. Unlike cefepime, the
activity of antipseudomonal penicillins such as TZP against
some of the Enterobacteriaceae with class 1 cephalosporinases is
dependent on the tazobactam component, which is relatively less
excreted in bile than piperacillin [32], while both the gut
penetration and the in vitro activity of piperacillin is superior to
that of cefepime against the major anaerobic pathogens [31].
Metronidazole (MTZ) was commonly added to cefepime by
prescribers in this study and differences in activity (between the
cefepime/MTZ combination and the antipseudomonal penicil-
lin/b-lactamase inhibitor combinations) against commensal
anaerobes may also be relevant. In the mouse model, disruption
of the gut microflora by a third-generation cephalosporins does
not spontaneously revert, unlike the effects of a penicillin
(ampicillin) [33]. An association between third-generation ceph-
alosporins [34] and cefepime [35] and increased prevalence of
resistant pathogens such as Clostridum difficile [36,37], P. aeruginosa
[38], antibiotic-resistant Enterobacteriaceae [39] and MRSA
[39,40,41] is well described. Lasting effects on the microflora,
as reported for other antibiotics [8,9], cannot be excluded in the
absence of long-term follow-up after ICU discharge but we found
Table 5. Colonisation of patients with MRSA or P. aeruginosa within portions of cycles.
MRSA P. aeruginosa
FEP APP-b FEP APP-b
Portion of cycle n/tested rate p n/tested rate p n/tested rate p n/tested rate p
First Half 21/68 0.31 0.076 24/70 0.34 0.211 15/68 0.22 0.006 32/70 0.46 0.018
Second Half 31/66 0.47 20/82 0.24 30/66 0.45 22/82 0.27
First third 16/50 0.32 21/47 0.45 14/50 0.28 23/47 0.49
Second Third 17/42 0.4 0.192 12/56 0.21 0.018 14/42 0.33 0.21 18/56 0.32 0.023
Last Third 19/42 0.45 11/49 0.22 17/42 0.4 13/49 0.27
p-values indicate significance between portions of cycles for each organism, by Chi-Squared analysis. FEP, cefepime; APP-b, antipseudomonal penicillin/b-lactamase
inhibitor combinations. Rate: proportion of patients positive.
doi:10.1371/journal.pone.0038719.t005
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fell to baseline in APP-b cycles, presumably as cefepime-exposed
admissions were discharged from ICU. MRSA and P. aeruginosa
infection rates also rose and fell according to cycle, and
underlying colonisation rates appeared to behave in the same
way.
Cefepime was associated with increased P. aeruginosa colonisa-
tion and infection, and significantly so for combined FEP cycles
(27/362) vs APP-b cycles (14/381) in Unit 1 (p 0.024). Ratios
between bacteraemia and respiratory infection and deep isolates
were similar between Units for MRSA and for methicillin-sensitive
S. aureus (MSSA), although respiratory infection was more
commonly reported in Unit 2 in general, and this included
Gram-negative pathogens as well as S. aureus (Table 6). Indeed, the
overwhelming source of all significant isolates in Unit 2 was
respiratory, at which site the attribution of significance to
pathogens such as MRSA and P. aeruginosa is problematic.
Nevertheless, rates of infection in fluids and tissues were similar
between Units, as expected given the similar casemix and acuity.
More frequent reporting of P. aeruginosa in Unit 2 (a burns referral
centre) may have arisen indirectly, through greater awareness of
the pathogen, and this would be another potential confounder.
Any bias introduced by relatively higher incidence of community
admissions to Unit 2 introduces would be expected to operate to
reduce rates of nosocomial Pseudomonas infection but Unit 2 also
reported a higher rate of urinary catheterization which, combined
with the possible variation in respiratory tract reporting, may
relatively increase apparent Pseudomonas infection rates. In any case
however, the fact that infection was less common in Unit 2 than
Unit 1 in almost every site including the bloodstream and that only
Unit 2 experienced P. aeruginosa bacteraemias suggests that the
difference is real. This is difficult to further clarify, although it is
reasonable to assume that any attribution of undue significance to
respiratory P. aeruginosa in Unit 2 and/or under-attribution in Unit
1 would be unaffected by cycling and remain relatively constant
from cycle to cycle.
Neither length of stay nor mortality changed significantly
overall in this study, despite the known consequences of
antibiotic-resistant infection [42]. In Unit 1, with the highest
MRSA incidence, MRSA infection complicated 8.7% of APP-b
cycle admissions, with more than a 60% increase (to 14.4%) in
cefepime cycle admissions. If MRSA infection doubles mortality
risk [43], a cohort of at least 1000 cefepime-treated patients
would be required to detect a difference over a baseline mortality
of 12%. A meta-analysis of 57 studies comparing cefepime with
another b-lactam antibiotic in more than 3000 patients with
sepsis reported an increased risk of all-cause mortality associated
with cefepime not long after this study closed recruiting, the
greatest difference being between TZP and FEP [12,44]. These
findings were later disputed [45] and then contradicted [46], but
discrepancies between the original data and the unpublished data
submitted by the drug sponsor [47] left the issue unresolved
[48,49]. Longer cycles or a larger study might have revealed
statistically stronger differences. A disproportionate incidence of
MRSA in Unit 1 and the absence of a second cefepime cycle in
Unit 2 are weaknesses, but clonal MRSA outbreaks in Unit 1 do
Table 6. Infection rates.
Source Organism Unit 1 Rate Unit 2 Rate p
e
blood MRSA 6 5.3 1 1.2
MSSA 6 5.3 1 1.2
Enterococcus 8 7.1 3 3.5
Streptococcus 32 . 6 ––
CNS
a 89 78.4 37 43.4
E. coli 3 2.6 1 1.2
Klebsiella 2 1.8 1 1.2
ESCPM
b 5 4.4 3 3.5
P. aeruginosa –– 22 . 4
bacterial total 122 109.3 49 57.5
(excl. CNS) 35 30.8 12 14.1 0.022
fluids and MRSA 2 1.8 – –
tissues
c MSSA 2 1.8 – –
Enterococcus –– 11 . 2
CNS 14 12.3 17 20.0
E. coli 4 3.5 3 3.5
Klebsiella 1 0.9 2 2.4
ESCPM –– 44 . 7
P. aeruginosa 5 4.4 3 3.5
Stenotrophomonas. 10 . 9 ––
bacterial total 29 25.6 30 36.2
(excl. CNS) 15 13.2 13 15.3 0.705
urine MRSA – – – –
MSSA – – 1 1.2
Enterococcus 9 7.9 2 2.4
CNS – – 1 1.2
E. coli 8 7.0 8 9.4
Klebsiella 4 3.5 2 2.4
ESCPM 7 6.2 3 3.5
P. aeruginosa 8 7.0 4 4.7
NF
d 1 0.9 1 1.2
bacterial total 37 32.6 22 25.8
(excl. CNS) 37 32.6 21 24.6 0.347
respiratory MRSA 40 35.2 8 9.4
MSSA 24 21.1 53 62.2
Enterococcus –– 11 . 2
S. pneumoniae –– 55 . 9
E. coli 11 9.7 21 24.6
Klebsiella 19 16.7 49 57.5
ESCPM 28 24.7 39 45.8
P. aeruginosa 32 28.2 28 32.9
NF 11 9.7 47 55.2
Haemophilus – – 17 20.0
bacterial total 165 145.4 268 314.6
(excl. NF) 154 135.7 221 259.4 ,0.001
Unique infections in all patients admitted to ICU (n=1987) are shown in
absolute numbers and in rates and a two-tailed test applied to compare the
rates per 1000 admissions;
aincludes all coagulase-negative staphylococci, and other organisms deemed to
be contaminants eg. Corynebacterium spp. and Micrococcus spp.;
bESCPM: Enterobacter, Serratia, Citrobacter, Proteus, Morganella spp.;
cincludes surgical specimens and drainage procedures;
dNF: glucose non-fermenting Gram-negative bacilli, including Acinetobacter
spp., Pseudomonas spp. Stenotrophomonas spp., etc.
eChi-Squared analysis.
doi:10.1371/journal.pone.0038719.t006
Table 6. Cont.
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detectably increased in our study by antibiotic cycling and
independently obtained data from NSW Health also showed that
MRSA acquisition rates did not increase in Unit 1 after the
cycling study (Figure S2).
Our data show that cefepime therapy is associated with
increased infection due to organisms resistant to the key antibiotics
used for management of sepsis and septic shock in intensive care.
Importantly, prescribing homogeneity per se does not appear to be
a specific resistance driver. The ecological influences of cefepime
seem to exceed that of all other risk factors in determining
infection risk and may be relevant to unexplained mortality
differences between cefepime and TZP in large studies of the
critically ill. Failure to consider ecological effects in setting
antibiotic policy may increase antibiotic resistance and even
contribute to unintended mortality.
Supporting Information
Figure S1 Temporal distribution of MRSA pulsotypes
within cycling period. ST: Sequence type (letters indicate
subgroups within STs at 95% identity). FEP: cefepime cycles;
APP-b: antipseudomonal penicillin combination cycles.
(TIF)
Figure S2 Monthly MRSA acquisition rates in Unit 1
before, during and after cycling (data from NSW Health
Dept), shown as patients positive per 100 bed days. FEP:
cefepime cycles; APP-b: antipseudomonal penicillin combination
cycle.
(TIF)
Table S1 Patient characteristics of all admissions in
which sampling was complete (n=206).
aMann-Whitney U
test or Chi-Squared analysis.
(DOC)
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